SCHEMBL19730144

SCHEMBL19730144

Cc1cc2[nH]cnc2c(N)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 1/20 0.44
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
KDM4E B2RXH2 3/20 0.42
APEX1 P27695 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
PRKCI P41743 1/20 0.36
PRNP P04156 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
RAD52 P43351 1/20 0.35
LMNA P02545 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22054004 0.80 MEN1 (0.41) PNPALDH1A1MAPTKDM4EAPEX1
SCHEMBL18398246 0.80 PNP (0.47) PNPALDH1A1MAPTKDM4EAPEX1
SCHEMBL19714843 0.78 PNP (0.46) PNPALDH1A1MAPTKDM4EAPEX1
SCHEMBL17253692 0.77 PNP (0.44) PNPALDH1A1MAPTKDM4EAPEX1
SCHEMBL29824853 0.77 MEN1 (0.39) PNPALDH1A1MAPTKDM4EMEN1
SCHEMBL23531664 0.77 MEN1 (0.39) PNPALDH1A1MAPTKDM4EMEN1
SCHEMBL19730160 0.77 PNP (0.44) PNPALDH1A1MAPTKDM4EAPEX1
SCHEMBL19738355 0.73 PNP (0.41) PNPALDH1A1MAPTKDM4EAPEX1
SCHEMBL17591328 0.71 PNP (0.46) PNPALDH1A1MAPTKDM4EAPEX1
SCHEMBL6581511 0.71 MEN1 (0.51) PNPALDH1A1MAPTKDM4EAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3889152-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2021-10-06 EP disclosed
US-20170362235-A1 ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF VASADE BIOSCIENCES, INC. 2017-12-21 US disclosed
US-20170362235-A1 ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF VASADE BIOSCIENCES, INC. 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362235-A1 ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF ADCY1, ADCY2, ADCY5 PNP 288/4885ALDH1A1 531/4885MAPT 4871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.